Want to see AU:ONE full AI Analyst Report?
Top Page
Oneview Healthcare Chess Depository Interests repr 1
(Sydney:ONE)
Select Model
Select Model
Rating:51Neutral
Price Target:
AU$0.14
▼(-17.06% Downside)
Action:Reiterated
Date:08/28/26
The score is held back mainly by weak financial performance (large ongoing losses and negative free cash flow), partially offset by improving operational indicators discussed on the earnings call (higher recurring mix, margin expansion, and reduced cash burn). Technicals show short-term strength but lack confirmation from the long-term trend, while valuation remains constrained by unprofitability and no dividend support in the provided data.
Positive Factors
Recurring Revenue Mix
The rising recurring-revenue mix makes the business more predictable and less dependent on deployment activity or hardware sales. Continued growth in subscriptions, supported by endpoint additions and renewal price increases, can improve revenue quality and support more durable margins.
Negative Factors
Persistent Net Losses
The scale of ongoing net losses relative to revenue shows that the company has not yet reached sustainable operating leverage. Continued losses can constrain reinvestment, keep the business reliant on financing, and make improved margins insufficient unless costs fall further or revenue expands materially.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring Revenue Mix
The rising recurring-revenue mix makes the business more predictable and less dependent on deployment activity or hardware sales. Continued growth in subscriptions, supported by endpoint additions and renewal price increases, can improve revenue quality and support more durable margins.
Read all positive factors
Oneview Healthcare Chess Depository Interests repr 1 (ONE) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$117.49M
Dividend YieldN/A
Average Volume (3M)80.24K
Price to Earnings (P/E)―
Beta (1Y)1.22
Revenue Growth-1.53%
EPS Growth28.29%
CountryAU
Employees87
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.01
Shares Outstanding839,533,900
10 Day Avg. Volume97,618
30 Day Avg. Volume80,240
Financial Highlights & Ratios
PEG Ratio0.76
Price to Book (P/B)47.09
Price to Sales (P/S)14.39
P/FCF Ratio-20.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.42Price Target Upside147.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.01
Revenue Forecast (FY)AU$13.00M
Oneview Healthcare Chess Depository Interests repr 1 Business Overview & Revenue Model
Company Description
Oneview Healthcare PLC provides specialized software solutions and expert consulting services to the healthcare industry. Its market reach extends across Ireland, the United States, Australia, Asia, and the Middle East. The company's core offering...
How the Company Makes Money
Oneview Healthcare’s revenue model is based on selling and supporting enterprise software solutions to hospitals and healthcare systems. The primary way the company makes money is through contracts for its patient engagement and clinical workflow ...
Oneview Healthcare Chess Depository Interests repr 1 Earnings Call Summary
Earnings Call Date:Aug 26, 2026
(Q2-2026)
| Next Earnings Date:Feb 19, 2027
Earnings Call Sentiment Positive
The call presents a predominantly positive operational and strategic picture despite headline revenue decline. Key strengths include significant recurring revenue growth (20% constant currency), a marked gross margin improvement (61% to 70%), reduced cash burn (‑15% YoY), a strengthened balance sheet via a $19m placement (pro‑forma EUR 11.4m), and meaningful commercial and product momentum — notably certification and pipeline from Epic's Bedside Hub and an expanded Baxter partnership. Principal negatives are the 14% reported revenue decline driven by currency effects and lower nonrecurring revenue, delayed endpoint deployments (notably the Children’s Hospital of Ireland) and competitive pricing pressures in Australia. On balance, strategic initiatives (Bedside Hub, Baxter, new front end, Ovie, AI productivity) and improved unit economics appear to outweigh near‑term revenue/currency headwinds.Positive Updates
Strong Recurring Revenue Growth (Constant Currency)
Recurring revenue grew 13% year‑over‑year on a reported basis and 20% on a constant currency basis, driven by new endpoint deployments and price increases; recurring revenue now represents 79% of total revenue (up from 60% a year ago).
Negative Updates
Headline Revenue Decline and Currency Headwinds
Total reported revenue fell 14% year‑over‑year (down 9% on a constant currency basis) due in part to the weakening U.S. dollar and Australian dollar versus the euro, and a decline in nonrecurring revenue of EUR 1.3m.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong Recurring Revenue Growth (Constant Currency)
Recurring revenue grew 13% year‑over‑year on a reported basis and 20% on a constant currency basis, driven by new endpoint deployments and price increases; recurring revenue now represents 79% of total revenue (up from 60% a year ago).
Read all positive updates
Company Guidance
Management guided to reach cash‑flow breakeven in the near term, driven by continued recurring‑revenue growth (H1 recurring revenue +13% reported, +20% constant currency; recurring now 79% of total revenue vs 60% a year ago), margin improvement (gross margin +9pp to 70% from 61%, gross profit €3.8m) and tighter cost control (cash OpEx -6% YoY, operating cash outflow -15% vs H1 2025, EBITDA loss €4.0m, an 11% improvement). They highlighted a pro‑forma cash position of €11.4m (cash €7.2m at 30 June plus the expected $7m/≈€4.2m tranche), a live endpoint base of ~15,000, a pipeline of 16 Bedside Hub opportunities representing >20,000 beds, 4 logos in late negotiation and a target to win another 3–4 Bedside Hub logos by year‑end; management also flagged meaningful ARR upside from these deals (new U.S. endpoints ~60% higher recurring revenue than recent Australian decommissions). Operational levers include product launches (new front end, Bedside Hub), AI efficiency gains (85% of code AI‑assisted, ~+170% feature velocity), observed renewal price increases of 15–20%, and further headcount/cost efficiencies (spend down ~10% since H2 2024) to support scalable growth.Oneview Healthcare Chess Depository Interests repr 1 Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.24M | 11.93M | 9.89M | 9.40M | 8.92M | 9.73M |
| Gross Profit | 7.48M | 7.12M | 6.67M | 6.16M | 5.35M | 5.31M |
| EBITDA | -4.48M | -10.48M | -10.82M | -7.89M | -11.51M | -7.42M |
| Net Income | -10.28M | -12.51M | -10.84M | -8.93M | -10.87M | -8.19M |
Balance Sheet | ||||||
| Total Assets | 15.32M | 15.49M | 25.96M | 21.92M | 12.75M | 21.09M |
| Cash, Cash Equivalents and Short-Term Investments | 7.19M | 4.60M | 13.83M | 11.55M | 6.41M | 15.18M |
| Total Debt | 1.02M | 1.11M | 1.15M | 935.32K | 543.01K | 1.20M |
| Total Liabilities | 8.88M | 11.84M | 12.71M | 12.78M | 10.50M | 11.19M |
| Stockholders Equity | 6.45M | 3.65M | 13.25M | 9.14M | 2.26M | 9.90M |
Cash Flow | ||||||
| Free Cash Flow | -3.79M | -8.38M | -10.52M | -7.79M | -10.24M | -4.09M |
| Operating Cash Flow | -7.87M | -8.32M | -10.47M | -7.26M | -10.20M | -4.03M |
| Investing Cash Flow | -224.61K | -116.31K | -459.78K | -521.38K | -44.52K | -65.26K |
| Financing Cash Flow | 6.69M | -294.26K | 13.14M | 13.04M | -100.11K | 12.22M |
Oneview Healthcare Chess Depository Interests repr 1 Technical Analysis
Negative
0.17
Price Trends
0.17
Negative
0.17
Negative
0.21
Negative
Market Momentum
>-0.01
Positive
35.33
Neutral
48.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ONE, the sentiment is Negative. The current price of 0.17 is above the 20-day moving average (MA) of 0.15, above the 50-day MA of 0.17, and below the 200-day MA of 0.21, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 35.33 is Neutral, neither overbought nor oversold. The STOCH value of 48.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ONE.
Oneview Healthcare Chess Depository Interests repr 1 Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | AU$133.63M | 58.24 | 2.53% | ― | 26.61% | 41.67% | |
56 Neutral | AU$47.67M | 19.06 | 90.90% | ― | 5.35% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$117.49M | -6.82 | -203.69% | ― | -1.53% | 28.29% | |
47 Neutral | AU$50.53M | -5.66 | -24.29% | ― | -17.35% | -47.29% | |
46 Neutral | AU$24.51M | -1.32 | -58.13% | ― | 2.08% | -195.31% | |
41 Neutral | AU$9.57M | -0.48 | -614.15% | ― | -46.09% | 70.70% |
* Healthcare Sector Average
AU:ONE
Oneview Healthcare Chess Depository Interests repr 1
0.14
-0.06
-30.00%
AU:M7T
Mach7 Technologies
0.22
-0.08
-27.12%
AU:BMT
Beamtree Holdings Ltd
0.08
-0.12
-58.50%
AU:AHE
MedAdvisor Limited
0.02
-0.02
-53.13%
AU:ALC
Alcidion Group Limited
0.10
<0.01
10.00%
AU:DOC
Doctor Care Anywhere Group PLC Shs Chess Depository Interests Repr 1 sh
0.13
-0.04
-25.71%
Oneview Healthcare Chess Depository Interests repr 1 Corporate Events
Oneview Healthcare Options Lapse Clarifies Capital Structure
Oct 2, 2026
Oneview Healthcare plc has reported the lapse of 46,000 options listed under ASX code ONEAE, which expired on September 30, 2026 after conditions attached to the options were not satisfied. The cessation of these conditional rights marginally redu...
Oneview Healthcare Cancels Over 500,000 Lapsed Restricted Share Units
Oct 2, 2026
Oneview Healthcare PLC has announced the cessation of 516,668 restricted share units after the conditional rights attached to these securities lapsed. The lapse occurred because the specified conditions were not met or became incapable of being sa...
Oneview Healthcare Issues New Tranche of Restricted Share Units
Oct 2, 2026
Oneview Healthcare PLC has notified the market of the issue of 737,977 restricted share units under its employee incentive scheme, recorded as unquoted equity securities on the ASX. The units, designated under the code ONEAF, are subject to transf...
Oneview Healthcare Lists Additional CDI Securities from Employee Incentive Scheme
Sep 1, 2026
Oneview Healthcare plc has applied for the quotation of 340,834 new CHESS Depositary Interests on the ASX, each representing a one-for-one interest in the company’s securities. These securities were previously issued under an employee incent...
Oneview Tightens Governance With Updated Continuous Disclosure Policy
Aug 27, 2026
Oneview Healthcare has updated its Continuous Disclosure Policy following a periodic review, formalising the roles and responsibilities of Authorised Contacts responsible for market communications. The changes also introduce strengthened procedure...
Oneview Healthcare Outlines H1 2026 Results and Growth Focus
Aug 27, 2026
Oneview Healthcare PLC has released its half-year 2026 results for the six months ended 30 June 2026, outlining its progress on a strategy aimed at scalable growth. The company presents its financial performance under IFRS alongside non-IFRS measu...
Oneview Healthcare Narrows Half-Year Loss as Recurring Revenue Rises but Asset Backing Thins
Aug 27, 2026
Oneview Healthcare reported a 13% increase in recurring revenue to €4.31 million for the six months to 30 June 2026, but non-recurring revenue fell 54%, pulling total revenue down 14% to €5.48 million year on year. The shift toward a h...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.